Local co-delivery of rhBMP-2 and cathepsin K inhibitor L006235 in poly(d,l-lactide-co-glycolide) nanospheres

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 105, Issue 1, 2017, Pages 136-144

  Yu, Nicole Y C ^a,b   Fathi, Ali ^c   Murphy, Ciara M ^a,b   Mikulec, Kathy ^a   Peacock, Lauren ^a   Cantrill, Laurence C ^a,b   Dehghani, Fariba ^c   Little, David G ^a,b   Schindeler, Aaron ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

bone morphogenetic protein; cathepsin K inhibitor; ectopic bone formation; local drug delivery; nanospheres

Indexed keywords

BONE; CELL CULTURE; COLLAGEN; COMPUTERIZED TOMOGRAPHY; NANOPARTICLES; NANOSPHERES; ORGANIC POLYMERS; TISSUE;

BONE MORPHOGENETIC PROTEINS; BONE TISSUE ENGINEERING; CATHEPSIN K; ECTOPIC BONE FORMATIONS; FLUORESCENT CONFOCAL MICROSCOPY; LOCAL DRUG DELIVERY; POLY(D ,L-LACTIDE-CO- GLYCOLIDE); STATISTICAL DIFFERENCES;

TISSUE ENGINEERING;

CATHEPSIN K INHIBITOR; COLLAGEN; HYDROXYAPATITE; L 006235; NANOCARRIER; NANOSPHERE; POLY( DEXTRO LACTIDE CO GLYCOLIDE) NANOSPHERE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; CATHEPSIN K; CRA 013783; POLYGLACTIN; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MASS; BONE TISSUE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME INHIBITION; FEMALE; FLUORESCENCE MICROSCOPY; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; SUSTAINED DRUG RELEASE; TISSUE ENGINEERING; TISSUE SCAFFOLD; TRANSMISSION ELECTRON MICROSCOPY; YOUNG ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; BENZAMIDES; BONE MORPHOGENETIC PROTEIN 2; CATHEPSIN K; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOSPHERES; OSTEOCLASTS; POLYGLACTIN 910; RECOMBINANT PROTEINS; THIAZOLES;

EID: 84946225964     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.33481     Document Type: Article

References (31)

1. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: An update. Injury 2005;36:S20–S27.
2. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J 2011;11:471–491.
3. Little DG, Ramachandran M, Schindeler A. The anabolic and catabolic responses in bone repair. J Bone Joint Surg [Br] 2007;89:425–433.
4. Yu NYC, Schindeler A, Mägil T, Ruys AJ, Little DG. Use of BMPs and bisphosphonates to improve bone fracture healing. Front Biosci (Elite Ed) 2012;4:2647–2653.
5. Yu NY, Schindeler A, Peacock L, Mikulec K, Fitzpatrick J, Ruys AJ, Cooper-White JJ, Little DG. Modulation of anabolic and catabolic responses via a porous polymer scaffold manufactured using thermally induced phase separation. Eur Cell Mater 2013;25:190–203.
6. Yu NY, Gdalevitch M, Murphy CM, Mikulec K, Peacock L, Fitzpatrick J, Cantrill LC, Ruys AJ, Cooper-White JJ, Little DG, Schindeler A. Spatial control of bone formation using a porous polymer scaffold co-delivering anabolic rhBMP-0000 and anti-resorptive agents. Eur Cell Mater 27:98–109.
7. Kurokouchi K, Ito T, Ohmori S, Kanda K, Murata Y, Yasukawa K, Izumi R, Inazu M, Iwata H, Seo H. Administration of bisphosphonate prevents disuse bone atrophy induced by tail suspension. Environ Med 1997;41:16–17.
8. Yamaguchi K, Masuhara K, Yamasaki S, Fuji T. Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty. J Orthop Sci 2005;10:32–36.
9. Stoch SA, Wagner JA. Cathepsin K inhibitors: A novel target for osteoporosis therapy. Clin Pharmacol Ther 2008;83:172–176.
10. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236–1238.
11. Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 2002;30:746–753.
12. Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, Duongle T. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012;27:524–537.
13. Bone HG, McClung M, Verbruggen N, Rybak-Feiglin A, DaSilva C, Santora AC, Ince A. A randomized double-blind, placebo-controlled study of a cathepsin K inhibitor in the treatment of postmenopausal women with low BMD: One year results. J Bone Miner Res 2007;22(Suppl 1):S37.
14. Adami S, Supronik J, Hala T, Brown JP, Garnero P, Haemmerle S, Ortmann CE, Bouisset F, Trechsel U. Effect of one year treatment with the cathepsin K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res 2006;21(Suppl 1):S24.
15. Cheng TL, Valtchev P, Murphy CM, Cantrill LC, Dehghani F, Little DG, Schindeler A. A sugar-based phase-transitioning delivery system for bone tissue engineering. Eur Cell Mater 2013;26:208–221.
16. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trend Pharmacol Sci 2008;29:22–28.
17. Soung do Y, Gentile MA, Duong le T, Drissi H. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice. Bone 2013;55:248–255.
18. Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, Venkatraman S, Tian ZQ, Burrill LC, Mendonca RV, Springman E, McCarter J, Chung T, Cheung H, Janc JW, McGrath M, Somoza JR, Enriquez P, Yu ZW, Strickley RM, Liu L, Venuti MC, Percival MD, Falgueyret JP, Prasit P, Oballa R, Riendeau D, Young RN, Wesolowski G, Rodan SB, Johnson C, Kimmel DB, Rodan G. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J Med Chem 2005;48:7520–7534.
19. Svelander L, Erlandsson-Harris H, Astner L, Grabowska U, Klareskog L, Lindstrom E, Hewitt E. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol 2009;613:155–162.
20. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84-A:2123–2134.
21. Gavenis K, Schneider U, Groll J, Schmidt-Rohlfing B. BMP-7-loaded PGLA microspheres as a new delivery system for the cultivation of human chondrocytes in a collagen type I gel: The common nude mouse model. Int J Artif Org 2010;33:45–53.
22. Murphy CM, Schindeler A, Gleeson JP, Yu NY, Cantrill LC, Mikulec K, Peacock L, O'Brien FJ, Little DG. A collagen-hydroxyapatite scaffold allows for binding and co-delivery of recombinant bone morphogenetic proteins and bisphosphonates. Acta Biomater 2014;10:2250–2258.
23. Wu ZM, Zhou L, Guo XD, Jiang W, Ling L, Qian Y, Luo KQ, Zhang LJ. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm 2012;425:1–8.
24. Bouxsein ML, Blake C, Luppen C, Cooper JA, Wozney JM, Seeherman HJ. Interaction between systemic bisphosphonate therapy and bone formation induced by local delivery of rhBMP-2 in non-human primates. J Bone Miner Res 2001;16:S234.
25. Castellanos IJ, Crespo R, Griebenow K. Poly(ethylene glycol) as stabilizer and emulsifying agent: A novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microspheres. J Control Release 2003;88:135–145.
26. Budhian A, Siegel SJ, Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul. 2005;22:773–785.
27. Karal-Yılmaz O, Serhatlı M, Baysal K, Baysal BM. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique. J Microencapsul 2011;28:46–54.
28. Ho HO, Lin CW, Sheu MT. Diffusion characteristics of collagen film. J Control Release 2001;77:97–105.
29. Schindeler A, Ramachandran M, Godfrey C, Morse A, McDonald M, Mikulec K, Little DG. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. J Orthop Res 2008;26:65–74.
30. Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26:242–251.
31. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(12 Suppl):2961–2978.